Earlier detection and precision medicine enhance lung cancer survival rates
2022-11-10
Earlier detection and precision medicine enhance lung cancer survival rates.
Check out below to see how molecular testing may help lung cancer patients make decisions about treatment.
About BGI Genomics
BGI Genomics, headquartered in Shenzhen China, is the world’s leading integrated solutions provider of precision medicine. Our services cover more than 100 countries and regions, involving more than 2,300 medical institutions. In July of 2017, as a subsidiary of BGI Group, BGI Genomics (300676.SZ) was officially listed on the Shenzhen Stock Exchange.